

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>2912-W0</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 00/ 08161</b>	International filing date (day/month/year) <b>28/03/2000</b>	(Earliest) Priority Date (day/month/year) <b>02/04/1999</b>
Applicant  <b>IMMUNEX CORPORATION et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

**USE OF SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR FOR TREATMENT HEART FAILURE**

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MORELAND L W ET AL: "Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein 'see comments!'"</p> <p>NEW ENGLAND JOURNAL OF MEDICINE, THE, US, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, vol. 337, no. 3, 17 July 1997 (1997-07-17), pages 141-147, XP002115639</p> <p>ISSN: 0028-4793</p> <p>page 141, column 1, line 10 - line 15</p> <p>---</p>	1
A	<p>BOZKURT, B. ET AL: "Pathophysiologically Relevant Concentrations of Tumor Necrosis Factor-alpha Promote Progressive Left Ventricular Dysfunction and Remodeling in Rats."</p> <p>CIRCULATION, vol. 97, no. 14, 14 April 1998 (1998-04-14), pages 1382-1391, XP000929170</p> <p>cited in the application</p> <p>abstract</p> <p>page 1384, paragraph 4</p> <p>page 1388, paragraph 2 -page 1389, paragraph 1</p> <p>---</p>	1
A	<p>WO 97 30088 A (KENNEDY INST OF RHEUMATOLOGY) 21 August 1997 (1997-08-21)</p> <p>cited in the application</p> <p>page 31, line 21 - line 24</p> <p>page 30, line 9 - line 29</p> <p>page 29, line 23</p> <p>page 28, line 2 - line 9</p> <p>---</p>	1
A	<p>WO 94 06476 A (IMMUNEX CORP)</p> <p>31 March 1994 (1994-03-31)</p> <p>page 16, line 30 - line 34; example 2</p> <p>page 2, line 12 - line 13</p> <p>abstract</p> <p>-----</p>	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/08161

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9730088 A	21-08-1997	CA 2246297 A EP 0882067 A JP 2000504716 T	21-08-1997 09-12-1998 18-04-2000
WO 9406476 A	31-03-1994	AU 670125 B AU 4920993 A CA 2123593 A EP 0620739 A JP 7504203 T NO 941780 A NZ 256293 A US 5605690 A	04-07-1996 12-04-1994 31-03-1994 26-10-1994 11-05-1995 15-07-1994 24-06-1997 25-02-1997

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/08161

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/17 A61K38/19

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DESWAL, A. ET AL: "A Phase I Trial Of Tumor Necrosis Factor Receptor (p75) Fusion Protein (TNFR:Fc) In Patients With Advanced Heart Failure" CIRCULATION, vol. 96, no. 8, 21 October 1997 (1997-10-21), page I-323 XP000925228 cited in the application abstract</p> <p style="text-align: center;">--- -/--</p>	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

24 July 2000

Date of mailing of the international search report

07/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Noë, V